Last reviewed · How we verify
Sinovac
Sinovac, marketed by the Albert B. Sabin Vaccine Institute, holds a significant position in its therapeutic area, though specific revenue figures are not provided. The drug's key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential market protection. However, the lack of detailed information on its mechanism, primary indication, and key trial results poses a significant risk in understanding its full competitive landscape and potential market threats.
At a glance
| Generic name | Sinovac |
|---|---|
| Sponsor | Albert B. Sabin Vaccine Institute |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial (PHASE3)
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- Impact of COVID-19 Vaccines on Cerebrovascular Health
- Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine (PHASE1)
- Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine (PHASE3)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinovac CI brief — competitive landscape report
- Sinovac updates RSS · CI watch RSS
- Albert B. Sabin Vaccine Institute portfolio CI